Clinical trial NCT06096363: Predictors of HFNC Failure in Patients With AHRF Using Echocardiography Parameters
Official title: Predictors of High-Flow Nasal Cannula Failure (HFNC) in Patients With Acute Hypoxemic Respiratory Failure (AHRF) Using Echocardiography Parameters
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Hypoxemic Respiratory Failure
Keywords: Echocardiography
Acute Hypoxemic Respiratory Failure
High Flow Nasal Cannula
Lead sponsor: Queen Mary Hospital, Hong Kong
Sponsor class: OTHER
First posted: 2023-10-23
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from acute hypoxemic respiratory requiring ventilatory support with high flow nasal cannula

Brief summary: Right ventricular dysfunction (RVD) and right ventricular-pulmonary arterial (RV-PA) uncoupling detected by transthoracic echocardiography (TTE) in acute respiratory distress syndrome (ARDS) are associated with poor survival. Early detection of RVD and RV-PA uncoupling in patients with acute hypoxemic respiratory failure (AHRF) may be indicative of worsening and decompensating pulmonary condition which may require escalation of respiratory support. The use of TTE parameters in predicting high-flow nasal cannula (HFNC) failure has not been previously studied. The objective of this study is to identify predictors of HFNC failure by TTE and to compare its performance with the well-established ROX index.


Eligibility criteria: Inclusion Criteria:

* Age ≧ 18; AND
* Acute hypoxemic respiratory failure (AHRF), defined by respiratory rate of greater than 25 breaths per minute and a ratio of the PaO2 to the fraction of inspired oxygen (PaO2 / FiO2) of less than 300, and use of accessory muscles of respiration or paradoxical abdominal motion; AND
* Required ventilatory support with high-flow nasal cannula (HFNC)

Exclusion Criteria:

* Patients suffering from hypercapnic respiratory failure; OR
* AHRF secondary to conditions that are indicated for non-invasive ventilation (NIV) (e.g. acute exacerbation of COPD, cardiogenic pulmonary edema); OR
* Use of NIV or invasive mechanical ventilation (IMV) prior to HFNC initiation; OR
* Patients with imminent need for endotracheal intubation and invasive mechanical ventilation (IMV); OR
* Patients with known or suspected diaphragm paralysis; OR
* Pregnancy; OR
* Patients with abdominal compartment syndrome; OR
* Use of HFNC for more than 12 hours prior to ICU admission; OR
* Patients with suboptimal echocardiographic image quality for data processing; OR

Primary outcomes:
measure: High-flow nasal cannula (HFNC) therapeutic failure
timeFrame: From the start of recruitment into study (i.e. start of HFNC use), till the date of study endpoint (i.e., step up to non-invasive ventilation, intubation, death on HFNC, or weaned off HFNC, whichever came first), assessed up to 4 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital
Study officials:
References: